prIME Oncology invites you to view a daily Webcast of interviews with Nordic Region Experts from the 45th ASCO Annual Meeting in Orlando, Florida.

Follow the links below to view the expert interviews conducted by Lee Lokey, MD, discussing key abstracts presented on Monday, June 1, 2009.

View Expert Interview with Professor Kjell E Öberg, MD, PhD 

View Expert Interview with Jan-Erik Frödin, MD

View Expert Interview with Petri Bono, MD, and Daniel Heinrich, MD

This clinical update focuses on the following data releases:

• Abstract #4508: Placebo-controlled double-blind prospective, randomized study of the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group
• Abstract #LBA4509: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
• Abstract #4503: Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicenter, randomized phase III trial (the UK ABC-02 trial)

• Abstract #LBA5019: Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206
• Abstract #5020: Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC)